Research Perspectives:

The NFκB pathway: a therapeutic target in glioblastoma

Lorena Nogueira, Patricia Ruiz-Ontañon, Alfonso Vazquez-Barquero, Francisco Moris and Jose L. Fernandez-Luna _

PDF  |  HTML  |  How to cite

Oncotarget. 2011; 2:646-653. https://doi.org/10.18632/oncotarget.322

Metrics: PDF 4368 views  |   HTML 4371 views  |   ?  


Lorena Nogueira1, Patricia Ruiz-Ontañon1, Alfonso Vazquez-Barquero2, Francisco Moris3 and Jose L. Fernandez-Luna1

1 Molecular Genetics Unit, , Hospital Valdecilla-IFIMAV, Santander, Spain

2 Service of Neurosurgery, Hospital Valdecilla-IFIMAV, Santander, Spain

3 Entrechem, Oviedo, Spain

Received: July 4, 2011; Accepted: September 1, 2011; Published: September 5, 2011;

Keywords: NFκB, glioblastoma, senescence, IKK inhibitor


Jose L. Fernandez-Luna, email:


  Cancer initiating cells have been described to be the only cell population with tumorigenic capacity in glioblastoma multiforme, one of the most aggressive and untreatable cancers. Recent work from our group described that NFκB pathway was activated in glioblastoma initiating cells undergoing differentiation, and that blockade of this activation promoted senescence of differentiating cells. NFκB activation in cancer may be the result of either exposure to proinflammatory stimuli in the tumor microenvironment or upregulation of the signaling pathway by upstream regulators. Appropriate control of NFκB activity, which can be achieved by gene modification or pharmacological strategies, would provide a potential approach for the management of NFκB related tumors, including glioblastoma. Here, we summarize the current knowledge of the relevance of NFκB in cancer and its possible role as a target of therapeutic intervention.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 322